Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Printable Liquid Metal Foams That Grow When Watered.
Krisnadi F, Kim S, Im S, Chacko D, Vong MH, Rykaczewski K, Park S, Dickey MD. Krisnadi F, et al. Among authors: im s. Adv Mater. 2024 Jan 22:e2308862. doi: 10.1002/adma.202308862. Online ahead of print. Adv Mater. 2024. PMID: 38252810
Injection Molding of Liquid Metal by Harnessing Nonstick Molds.
Ma J, Vaghani DP, Im S, Kong M, Shamsi M, Wei S, Vong MH, Dickey MD. Ma J, et al. Among authors: im s. ACS Appl Mater Interfaces. 2024 Feb 28;16(8):10931-10941. doi: 10.1021/acsami.3c16692. Epub 2024 Feb 20. ACS Appl Mater Interfaces. 2024. PMID: 38377555
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J. Hurvitz SA, et al. Among authors: im sa. ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24. ESMO Open. 2024. PMID: 38796287 Free article. Clinical Trial.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.
Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, Yoshino T, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N. Park KH, et al. Among authors: im sa. ESMO Open. 2024 May;9(5):102974. doi: 10.1016/j.esmoop.2024.102974. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38796284 Free article.
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
Lu YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. Lu YS, et al. Among authors: im sa. J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. Online ahead of print. J Clin Oncol. 2024. PMID: 38771995
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J. Dent R, et al. Among authors: im sa. Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.04.001. Online ahead of print. Ann Oncol. 2024. PMID: 38755096 Free article.
2,530 results